Biocompatible strain sensors for continuous monitoring of tumor progression during immunotherapy treatments

生物相容性应变传感器，用于在免疫治疗过程中持续监测肿瘤进展

• 批准号: 10163050
• 负责人: Alex Abramson
• 金额: $ 6.6万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-08 至 2022-05-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10163050
• 关键词: Aftercare; Animals; Area; Back; Biosensor; Body Temperature; Breast Cancer Model; Cell Death; Cells; Clinical; Combination immunotherapy; Communication; Data; Development; Devices; Disease; Drug Combinations; Drug Prescriptions; Electric Conductivity; Ensure; Exhibits; Fatty acid glycerol esters; Goals; Growth; Health Professional; Hour; Image; Imaging Techniques; Immune; Immune checkpoint inhibitor; Immunotherapy; Implant; Individual; Kinetics; Location; Malignant Neoplasms; Mammary Neoplasms; Measurement; Measures; Mechanics; Methods; Modeling; Molecular; Monitor; Mouse Mammary Tumor Virus; National Institute of Biomedical Imaging and Bioengineering; Outcome; Output; PET/CT scan; Patients; Pattern; Peripheral; Pharmaceutical Preparations; Physiologic pulse; Polymers; Power Sources; Process; Reading; Research; Research Personnel; Resistance; Scanning; Series; Signal Transduction; Stress; Stretching; Subcutaneous Tissue; System; Techniques; Technology; Technology Transfer; Telemetry; Temperature; Tendon structure; Testing; Therapeutic; Time; Tissues; Treatment Efficacy; Treatment Protocols; Tumor Burden; Wireless Technology; X-Ray Computed Tomography; biomaterial compatibility; cancer therapy; checkpoint therapy; clinically relevant; cost; data exchange; design; electric impedance; experience; experimental study; flexibility; follow-up; implantation; implanted sensor; mammary; microCT; minimally invasive; mouse model; new technology; prevent; programmed cell death protein 1; response; sensor; standard of care; subcutaneous; success; treatment effect; treatment strategy; trend; tumor; tumor growth; tumor progression; wireless communication

Project Summary/Abstract: Checkpoint inhibitor therapies provide the ability to treat several previously intractable tumor types; however, only a fraction of patients eligible for the medications respond favorably. Currently patients receiving these treatments must undergo a series of costly imaging sessions to determine their tumor’s response to the medication, yet imaging only provides a static picture of the disease. Health care professionals often wait months before ordering imaging sessions in order to ensure that meaningful tumor growth or recession has occurred according to the iRECIST criteria. The goal of this proposed research is to develop an implantable strain sensor to continuously monitor tumor size throughout the treatment and provide clinicians and cancer researchers with the ability to monitor tumor kinetics. We plan to treat a mouse model for mammary cancer with a combination immunotherapy treatment and use our sensor to continuously detect minute changes in tumor size. We will then look for trends in the data that may provide clues of a positive response, especially within the first 48 hours after treatment when immune cells are known to infiltrate the tumor and cause it to temporarily expand. We hope that this new technology will be used as a method for clinicians to more accurately determine the best time to take a follow up CT scan, and we also believe that this technology could be used to study the relationship between molecular signals and tumor progression. However, in order to develop this type of sensor, we must overcome two fundamental design constraints: the large size associated with power storage and wireless data transfer; and the ability for a sensor to grow and conform to rapidly expanding tissue. Part of the proposed research is to develop a platform technology for transferring power and sensor readings conductively through the body, thereby eliminating the need for a battery and telemetry system and shrinking the device size significantly. We also plan to utilize flexible and stretchable electronic materials developed in our lab to design a device which can expand alongside tissue without exerting any force that could damage the surrounding tissue. We believe that these technologies could be used for a variety of purposes in addition to measuring tumor size and could enable to widespread routine clinical use of implantable biomedical sensors.

项目摘要/摘要： 然而，检查点抑制剂疗法提供了治疗几种以前难以治愈的肿瘤类型的能力； 目前，只有一小部分符合这些药物治疗条件的患者有良好的反应。 治疗必须经过一系列昂贵的成像检查，以确定肿瘤对治疗的反应 药物治疗，但影像学只能提供疾病的静态图像，医疗保健专业人员通常要等待数月。 在预约影像检查之前，以确保发生有意义的肿瘤生长或衰退 根据 iRECIST 标准，这项研究的目标是开发一种植入式应变传感器。 在整个治疗过程中持续监测肿瘤大小，并为高级和癌症研究人员提供 我们计划通过组合治疗小鼠乳腺癌模型。 然后我们将进行免疫疗法治疗并使用我们的传感器连续检测肿瘤大小的微小变化。 寻找可能提供积极反应线索的数据趋势，尤其是在发生后的前 48 小时内 当已知免疫细胞浸润肿瘤并导致其暂时扩大时进行治疗。 这项新技术将被用作人群更准确地确定最佳拍摄时间的方法 后续CT扫描，我们也相信这项技术可以用来研究之间的关系 然而，为了开发这种类型的传感器，我们必须克服一些困难。 两个基本的设计限制：与电力存储和无线数据传输相关的大尺寸； 传感器生长并适应快速扩张的组织的能力是拟议研究的一部分。 开发一种通过身体传导电力和传感器读数的平台技术，从而 我们还计划消除对电池和遥测系统的需求并显着缩小设备尺寸。 利用我们实验室开发的柔性和可拉伸的电子材料来设计一种可以扩展的设备 我们相信这些可以与组织并排，而不施加任何可能损坏周围组织的力。 除了测量肿瘤大小之外，技术还可以用于多种目的，并且可以 植入式生物医学传感器在临床上广泛使用。